Clinical Trial Update: Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2) [Phase 2]

View source ↗

Summary

Phase 2 study assessing antiviral effect, safety, and pharmacokinetics of Boehringer Ingelheim BI-201335 combined with PegIFN/RBV in chronic hepatitis C genotyp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BI 201335
• Pegylated interferon alfa-2a (Peginterferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2015-11-16